Obinutuzumab in Treatment of Fibrillary Glomerulonephritis
Part of paid clinical trials in Rochester, Minnesota.
- Sponsor
- Mayo Clinic
- Study ID
- NCT06295770
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Fibrillary Glomerulonephritis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Obinutuzumab — DRUGObinutuzumab 1g IV on day one and 1 g IV on day 15, followed by identical course at month 6.
Study Details
The purpose of this research is to learn if Obinutuzumab is effective and safe in treating patients with fibrillary glomerulonephritis (FGN).
Key Dates
- Start date
- Jun 24, 2024
- Status verified
- Apr 2026
- Primary completion
- Dec 31, 2026
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 20 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Obinutuzumab in Treatment of Fibrillary GlomerulonephritisPatients with biopsy proven fibrillary GN who have \>1 gram/24 hour of proteinuria and eGFR ≥ 20 ml/min/BSA will be treated with Obinutuzumab.
Primary Outcome Measure
Change in proteinuria from baseline to 12 months post treatment with Obinutuzumab [ Time Frame: Baseline, 6 months, 12 months ]
Central Contacts
- Nicholas Geroux507-266-0956
- Corbyn Bendtsen507-284-0366
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mayo Clinic | Rochester | Minnesota | 55905 | Ladan Zand (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Rochester, MN
By research site